Temporal trends in admissions for atrial fibrillation and severe bleeding in England: an 18-year longitudinal analysis

References

• Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14(3):195–203.
   PubMedGoogle Scholar
• Kornej J, Borschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4–20.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med. 1987;147(9):1561–1564.
   PubMedGoogle Scholar
• Ben Freedman S, Gersh BJ, Lip GY. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J. 2015;36(11):653–656.
   PubMed Web of Science ®Google Scholar
• Zaidel EJ, Leng X, Adeoye AM, et al. Inclusion in the World Health Organization model list of essential medicines of non-vitamin K anticoagulants for treatment of non-valvular atrial fibrillation: a step towards reducing the burden of cardiovascular morbidity and mortality. Glob Heart. 2020;15(1):52.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147(8):590–592.
   PubMed Web of Science ®Google Scholar
• Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;2005(3):CD001927.
   PubMedGoogle Scholar
• Blin P, Dureau-Pournin C, Lassalle R, et al. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol. 2016;81(3):569–578.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Barnes GD, Lucas E, Alexander GC, et al. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300–1305 e1302.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–2484.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.
   PubMed Web of Science ®Google Scholar
• Mueller T, Alvarez-Madrazo S, Robertson C, et al. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85(2):422–431.
   PubMed Web of Science ®Google Scholar
• Bouget J, Oger E. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thromb Res. 2015;136(6):1190–1194.
   PubMed Web of Science ®Google Scholar
• Marco Garbayo JL, Koninckx Canada M, Perez Castello I, et al. Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. Eur J Hosp Pharm. 2019;26(2):106–112.
   PubMedGoogle Scholar
• Badal M, Aryal MR, Mege J, et al. Evaluation of trends of inpatient hospitalisation for significant haemorrhage in patients anticoagulated for atrial fibrillation before and after the release of novel anticoagulants. Heart Lung Circ. 2015;24(1):94–97.
   PubMed Web of Science ®Google Scholar
• Ganetsky M. Trends and characteristics of emergency department patients prescribed novel oral anticoagulants. J Emerg Med. 2015;49(5):693–697.
   PubMed Web of Science ®Google Scholar
• Lane DA, Skjoth F, Lip GYH, et al. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017;6.
   PubMed Web of Science ®Google Scholar
• Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13(8):1110–1117.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125.
   PubMed Web of Science ®Google Scholar
• Lee SR, Choi EK, Lee SY, et al. Temporal trends of emergency department visits of patients with atrial fibrillation: a nationwide Population-Based study. J Clin Med. 2020;9(5):1485.
   Web of Science ®Google Scholar
• Wong KY, Davies B, Adeleke Y, et al. Hospital admissions for stroke and bleeding in Hounslow following a quality improvement initiative. Open Heart. 2021;8(1):e001558.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dondi L, Andreotti F, et al. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. Am Heart J. 2020;220:12–19.
   PubMed Web of Science ®Google Scholar
• Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–953.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004;110(9):1042–1046.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ. 2007;335(7616):383.
   PubMedGoogle Scholar
• Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167–1176.
   PubMed Web of Science ®Google Scholar
• Forbes LJ, Marchand C, Doran T, et al. The role of the quality and outcomes framework in the care of long-term conditions: a systematic review. Br J Gen Pract. 2017;67(664):e775–e784.
   PubMed Web of Science ®Google Scholar
• Ho KH, van Hove M, Leng G. Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC Health Serv Res. 2020;20(1):279.
   PubMed Web of Science ®Google Scholar
• Afzal S, Zaidi STR, Merchant HA, et al. Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. J Thromb Thrombolysis. 2021;52(2):646–653.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Downing J, Daras K, et al. Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. BMJ Open. 2020;10(5):e033357.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
   PubMedGoogle Scholar
• Jun M, Lix LM, Durand M, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017;359:j4323.
   PubMedGoogle Scholar
• European Medicines Agency. [cited 2020 Mar 27; assessed 2021 May 24]. Amsterdam, The Netherlands: European Medicines Agency. Available from: https://www.ema.europa.eu/en/documents/press-release/no-change-needed-use-direct-oral-anticoagulants-following-ema-funded-study_en.pdf
   Google Scholar
• Jackevicius CA, Lu L, Ghaznavi Z, et al. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(2):e007230.
   PubMed Web of Science ®Google Scholar
• Radadiya D, Devani K, Brahmbhatt B, et al. Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter? - a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e50–e58.
   PubMedGoogle Scholar
• Protty MB, Hayes J. Dawn of the direct-acting oral anticoagulants: trends in oral anticoagulant prescribing in Wales 2009-2015. J Clin Pharm Ther. 2017;42(2):132–134.
   PubMed Web of Science ®Google Scholar